Quest Diagnostics Incorporated’s Stock Price Skyrockets to $172.84, Witnessing a Whopping 6.78% Upsurge

Quest Diagnostics Incorporated (DGX)

172.84 USD +10.98 (+6.78%) Volume: 2.42M

Quest Diagnostics Incorporated’s stock price soared to 172.84 USD, marking a significant trading session gain of +6.78%. With a robust trading volume of 2.42M and an impressive year-to-date percentage change of +14.57%, DGX continues to demonstrate strong stock market performance.

Latest developments on Quest Diagnostics Incorporated

Quest Diagnostics has seen a surge in its stock price following the release of its first quarter 2025 financial results, which exceeded expectations. The company reported strong earnings bolstered by a March rebound, leading to a 3% increase in its stock price. Quest Diagnostics reaffirmed its revenue and adjusted diluted EPS guidance for the full year, further boosting investor confidence. With better-than-expected earnings and a positive outlook, Quest Diagnostics has garnered a buy rating and seen an 8% increase in its stock price. The company’s strategic moves and revenue rebound have fueled outlook confidence, with its Q1 performance shining with strong profits and revenue growth. Overall, Quest Diagnostics looks like a ‘safe haven’ for investors after beating quarterly profit estimates and exceeding revenue projections.

Quest Diagnostics Incorporated on Smartkarma

Analysts at Baptista Research are bullish on Quest Diagnostics, highlighting the company’s enhanced offerings in cardiometabolic testing and autoimmune disorders as catalysts for growth. According to their research report, Quest Diagnostics reported strong financial performance for the fourth quarter and full year of 2024, with revenue growth driven by acquisitions and organic growth. The company’s revenue for the fourth quarter increased by 14.5% to $2.62 billion, with organic revenue growth accounting for nearly 5%. The completion of eight acquisitions, including LifeLabs in Canada, has bolstered Quest Diagnostics‘ market position and expanded its geographic reach.

In another report by Baptista Research, analysts continue to express bullish sentiment towards Quest Diagnostics, emphasizing the company’s expansion into new markets through strategic acquisitions as a critical growth catalyst. The research highlights Quest Diagnostics‘ robust performance for the third quarter of the fiscal year, marked by a total revenue growth of 8.5% and organic growth of 4.2%. Strategic initiatives such as new customer acquisitions, expanding business with existing customers, and completing three acquisitions, including the significant acquisition of LifeLabs, have contributed to the company’s success. These efforts not only underline growth but also support the accelerated strategy aimed at scaling operations in Canada and broadening Quest Diagnostics‘ U.S. market presence.

A look at Quest Diagnostics Incorporated Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Quest Diagnostics, a company that provides diagnostic testing and services, has received a mix of scores in various categories according to Smartkarma Smart Scores. While the company scored well in Dividend and Momentum, with scores of 4 each, it received average scores in Value, Growth, and Resilience, with scores of 3 each. This suggests that Quest Diagnostics may offer a good dividend yield and have positive market momentum, but its overall outlook in terms of value, growth, and resilience is more moderate.

Despite the mixed scores, Quest Diagnostics remains a key player in the diagnostic testing industry. The company operates a national network of laboratories and service centers, providing a range of testing services including esoteric testing, routine medical testing, and drugs of abuse testing. With its established presence in the market, Quest Diagnostics is well-positioned to continue serving the healthcare industry and meeting the diagnostic needs of patients and healthcare providers.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma